Accordingly, the identification of reliable biomarkers, such as GRβ expression and STAT3 activation, cytokine profiles, among others, that can enable an early diagnosis and guide personalized management of GCI holds great promise, and these biomarkers may also evaluate therapeutic responses relevant to improving outcome in patients with asthma. This evidence concerns the gene STAT3 and asthma.